Results 31 to 40 of about 3,675 (177)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Reversal of HIV-1 latency with anti-microRNA inhibitors [PDF]

The International Journal of Biochemistry & Cell Biology, 2009
Human immunodeficiency virus type 1 (HIV-1) latency is achieved when host cells contain integrated proviral DNA but do not produce viral particles. The virus remains in resting CD4 T-lymphocytes, evading host immune surveillance and antiviral drugs. When resting cells are activated, infectious viral particles are produced.
openaire   +2 more sources

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption [PDF]

Journal of Virology, 2017
ABSTRACT There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on long-term antiretroviral therapy (ART) and may not be sufficient to eliminate ...
Lee, WS, Kristensen, AB, Rasmussen, TA, Tolstrup, M, Østergaard, L, Søgaard, OS, Wines, BD, Mark Hogarth, P, Reynaldi, A, Davenport, MP, Emery, S, Amin, J, Cooper, DA, Kan, VL, Fox, J, Gruell, H, Parsons, MS, Kent, SJ   +17 more
openaire   +6 more sources

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

PLOS Pathogens, 2015
Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results.
Søgaard, OS, Graversen, ME, Leth, S, Olesen, R, Brinkmann, CR, Nissen, SK, Kjaer, AS, Schleimann, MH, Denton, PW, Hey-Cunningham, WJ, Koelsch, KK, Pantaleo, G, Krogsgaard, K, Sommerfelt, M, Fromentin, R, Chomont, N, Rasmussen, TA, Østergaard, L, Tolstrup, M   +18 more
openaire   +8 more sources

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA [PDF]

Biology Open, 2020
Infection of HIV-1 remains incurable because long-lived, latently-infected cells persist during prolonged antiretroviral therapy. Attempts to pharmacologically reactivate and purge the latent reservoir with latency reactivating agents (LRAs) such as protein kinase C (PKC) agonists (e.g. ingenol A) or histone deacetylase (HDAC) inhibitors (e.g.
Jared P. Taylor, Lucas H. Armitage, Daniel L. Aldridge, Melanie N. Cash, Mark A. Wallet   +4 more
openaire   +3 more sources

Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. [PDF]

Antimicrob Agents Chemother, 2018
Antiretroviral therapy (ART) does not cure HIV-1 infection due to the persistence of proviruses in long-lived resting T cells. Strategies targeting these latently infected cells will be necessary to eradicate HIV-1 in infected individuals.
Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V.   +6 more
europepmc   +4 more sources

T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin.

PLoS Pathogens, 2022
The reservoir of latently HIV-1 infected cells is heterogeneous. To achieve an HIV-1 cure, the reservoir of activatable proviruses must be eliminated while permanently silenced proviruses may be tolerated.
Birgitta Lindqvist, Bianca B Jütte, Luca Love, Wlaa Assi, Julie Roux, Anders Sönnerborg, Tugsan Tezil, Eric Verdin, J Peter Svensson   +8 more
doaj   +1 more source

A Comparison of Different Immune Activation Strategies to Reverse HIV-1 Latency

Open Forum Infectious Diseases, 2020
AbstractResting CD4+ T cells are the best characterized component of the latent reservoir. Activation of these CD4+ T cells is needed to optimize transcription and viral replication, and this strategy has been used to measure the inducible reservoir. There are several methods that can be used to activate CD4+ T cells, and in this study, we compared 3 ...
Garliss, Caroline C, Kwaa, Abena K, Blankson, Joel N   +2 more
openaire   +2 more sources

Curaxin CBL0137 has the potential to reverse HIV‐1 latency

Journal of Medical Virology, 2019
AbstractA cure for human immunodeficiency virus type‐1 (HIV‐1) has been hampered by the limitation of current combination antiretroviral therapy (cART) to address the latent reservoirs in HIV‐1 patients. One strategy proposed to eradicate these reservoirs is the “shock and kill” approach, where latency‐reversing agents (LRAs) are used to reactivate and
Maxime J. Jean, Dawei Zhou, Guillaume Fiches, Weili Kong, Huachao Huang, Andrei Purmal, Katerina Gurova, Netty G. Santoso, Jian Zhu   +8 more
openaire   +3 more sources

UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of Tat

mBio, 2021
HIV-1 remains incurable due to viral reservoirs, which lead to durably latent HIV infection. Identifying novel host factors and deciphering the molecular mechanisms involved in the establishment and maintenance of latency are critical to discover new ...
Taizhen Liang, Qiao Zhang, Ziyao Wu, Pei Chen, Yifan Huang, Shuwen Liu, Lin Li   +6 more
doaj   +1 more source